[1. Baraka A, AbdelGawad H. Targeting apoptosis in the heart of streptozotocin-induced diabetic rats. J Cardiovasc Pharm Ther. 2010; 15:175-81.10.1177/1074248409356557]Open DOISearch in Google Scholar
[2. Quercioli A, Mach F, Montecucco F. Novel treatment strategy with direct renin inhibition against heart failure. Panminerva Med.2010; 52:41-51.]Search in Google Scholar
[3. Kang BY, Mehta JL. Rosuvastatin attenuates ang IImediated cardiomyocyte hypertrophy via inhibition of LOX-1. J Cardiovasc Pharm Ther .2009; 14:283-91.10.1177/1074248409344329]Open DOISearch in Google Scholar
[4. Zanfolin M, Faro R, Araujo EG, Guaraldo AMA, Antunes E, De Nucci G. Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J Cardiovasc Pharm Ther. 2006; 47:391-5.10.1097/01.fjc.0000210071.54828.9b]Search in Google Scholar
[5. Frey N, Olson E N. Cardiac hypertrophy: the good, the bad and the ugly. Annu Rev Physiol. 2003; 65: 45-79.10.1146/annurev.physiol.65.092101.142243]Open DOISearch in Google Scholar
[6. Majak P, Bjornstad J, Vengen OA, et al. Plasma IL-18 and IL-18BP are altered differently in reverse remodeling following aortic valve replacement. Scand Cardiovasc J. 2010; 44:113-8.10.3109/14017430903426902]Open DOISearch in Google Scholar
[7. Tajsharghi H, Fyhr IM. Structural effects of the slow/ b-cardiac myosin heavy chain R453C mutation in cardiac and skeletal muscle. Scand Cardiovasc J. 2008; 42:153-6.10.1080/14017430701762701]Open DOISearch in Google Scholar
[8. van Kesteren CA, van Heugten HA, Lamers JM, et a1. Angiotensin II mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts. J Mol Cell Cardiol. 1997; 29:2147-57.10.1006/jmcc.1997.0448]Open DOISearch in Google Scholar
[9. Cohn JN, Ferrari R, Sharpe N. Cardiac remodelingconcepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf on an international forum on cardiac remodeling. J Am Coll Cardiol. 2000; 35:569-82.10.1016/S0735-1097(99)00630-0]Open DOISearch in Google Scholar
[10. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target. Circulation. 2004; 109:1580-9.10.1161/01.CIR.0000120390.68287.BB]Open DOISearch in Google Scholar
[11. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54.10.1016/0003-2697(76)90527-3]Open DOISearch in Google Scholar
[12. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T, et al. Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res. 1995; 77:258-65.10.1161/01.RES.77.2.2587614712]Open DOISearch in Google Scholar
[13. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, et a1. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res. 2007. 75: 29-39.10.1016/j.cardiores.2007.04.00717499227]Open DOISearch in Google Scholar
[14. Randsbaek F, Lund S, Kimose HH, Grove E, B tker HE, Schmitz O, et al. Angiotensin II inhibition increases cellular glucose transport during reperfusion but not ischemia in pig hearts. Scand Cardiovasc J. 2003; 37: 205-10.10.1080/1401743031000204012944208]Open DOISearch in Google Scholar
[15. Sugden PH. Signalling pathways in cardiac myocyte hypertrophy. Ann Med. 2001; 33:611-22.]Search in Google Scholar
[16. Zhang S, Yan Y, Daubert RA, Schnellmann RG. ERK promotes hydrogen peroxide-induced apoptosis through caspase-3 activation and inhibition of Akt in renal epithelial cells. Am J Physiol Renal Physiol. 2007; 292:F440-7.10.1152/ajprenal.00170.200616885155]Search in Google Scholar
[17. Wang J, Shen YH, Utama B. HCMV infection attenuates hydrogen peroxide induced endothelial apoptosis-involvement of ERK pathway. FEBS Lett. 2006; 580:2779-87.10.1016/j.febslet.2006.04.04116650413]Search in Google Scholar
[18. Blanc A, Pandey NR, Srivastava AK. Synchronous activation of ERK1/2, p38mapk and PKB/Akt signaling by H2O2 in vascular smooth muscle cells: potential involvement in vascular disease. Int J Mol Med. 2003; 11:229-34.]Search in Google Scholar
[19. Hunyady L, Tuna G. The role of the AT1 angiotensin receptor incardiac hypertrophy: angiotensin II receptor or stretch sensor. Trends Endocfinol Metab. 2004; 15: 405.10.1016/j.tem.2004.09.00315519886]Search in Google Scholar
[20. Zhang SQ, Ding B, Guo ZG. Inhibitory effect of antisense oligodeoxynucleotide to p44/p42 MAPK on angiotensin II induced hypertrophic response in cultured neonatal rat cardiac myocyte. Acta Pharmacol Sin. 2004; 25:41-6.]Search in Google Scholar
[21. Fountoulaki K, Dimopoulos V, Giannakoulis J, Zintzaras E, Triposkiadis F. Left ventricular mass and mechanics in mild-to-moderate hypertension: Effect of nebivolol versus telmisartan. Am J Hypertens. 2005; 18:171-7.10.1016/j.amjhyper.2004.08.03915752943]Open DOISearch in Google Scholar
[22. Mattioli AV, Zennaro M, Bonatti S, Bonetti L, Mattioli G. Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol. 2004; 97:383-8.10.1016/j.ijcard.2003.10.01815561322]Open DOISearch in Google Scholar